At the last check on Friday, Eli Lilly and Company’s (NYSE:LLY) stock was up $6.67, moving up 1.24 percent to $544.33. The average number of shares traded per day over the past five days has been 2,649,333 shares. 3 times new highs have been achieved over the past 5 days, with a $15.92 gain in that time frame. In the last twenty days, the average volume was 3,125,408, while in the previous 50 days, it was 2,866,387.
Since last month, LLY stock rose 17.36%. Shares of the company fell to $446.56 on 07/26/23, the lowest level in the past month. A 52-week high of $552.87 was reached on 08/16/23 after having rallying from a 52-week low of $296.32. Since the beginning of this year, LLY’s stock price has risen by 48.79% or $178.37, and marked a new high 30 times. However, the stock has declined by -1.54% since its 52-week high.
LLY stock investors should be aware that Eli Lilly and Company (LLY) stock had its last reported insider trading activity 3 days ago on Aug 15. LILLY ENDOWMENT INC, the 10% Owner of the company, disposed of 50,222 shares for $543.72 on Aug 15. It resulted in a $27,306,747 divestment by the insider. LILLY ENDOWMENT INC sold 164,778 shares at an average price of $539.08 on Aug 14. The insider now owns 100,449,032 shares following the transaction. On Aug 11, 10% Owner ELI LILLY & Co bought 1,718,493 shares at $14.92 apiece. The transaction was valued at $25,639,916.
Valuation Metrics
Right now, Eli Lilly and Company (LLY) has a P/E ratio of about 75.62. The stock’s beta is 0.29. Besides these, the trailing price-to-sales (P/S) ratio of 17.28, the price-to-book (PB) ratio of 44.24, and the price-to-cash flow ratio of 158.79 may also be considered.
The latest dividend of $1.13 per share was paid out, remained unchanged from last year’s $1.13. On Monday December 12 2022, a $0.15 dividend increase was announced.
Financial Health
In the three months ended June 29, Eli Lilly and Company’s quick ratio stood at 0.90, while its current ratio was 1.10, showing that the company is not able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending June 29 was 1.64, and the total debt-to-equity ratio was 1.70. On the profitability front, the trailing twelve-month gross margin is 77.80% percent. Based on annual data, LLY earned $21.91 billion in gross profit and brought in $28.54 billion in revenue.
In Eli Lilly and Company’s quarter-end financial report for June 29, it reported total debt of $18.16 billion against cash and short-term investments of $134.6 million. According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. LLY’s revenue rose 21.95% to $6.96 billion during the quarter, while net income inched up to $8.31 billion. While analysts expected Eli Lilly and Company to report $1.98 quarterly earnings, the actual figure was $2.11 per share, beating the consensus estimate by 6.60%. During the quarter, the company generated $2.49 billion in EBITDA. The liabilities of Eli Lilly and Company were 43.66 billion at the end of its most recent quarter ended June 29, and its total debt was $18.95 billion. The value of shareholders’ equity is $949.29 million.
Technical Picture
This quick technical analysis looks at Eli Lilly and Company’s (LLY) price momentum. With a historical volatility rate of 66.79%, the RSI 9-day stood at 78.18% on 17 August.
With respect to its five-day moving average, the current Eli Lilly and Company price is up by +3.01% percent or $15.92. At present, LLY shares trade +17.78% above its 20-day simple moving average and +62.64% percent above its 100-day simple moving average. However, the stock is currently trading approximately +24.71% above its SMA50 and +50.30% above its SMA200.
Stochastic coefficient K was 90.41% and Stochastic coefficient D was 93.17%, while ATR was 13.59. Given the Stochastic reading of 91.82% for the 14-day period, the RSI (14) reading has been calculated as 76.16%. As of today, the MACD Oscillator reading stands at 8.24, while the 14-day reading stands at 37.67.
Analyst Ratings
Jefferies upgraded its rating on Eli Lilly and Company (NYSE: LLY) to a Buy in a note to investors on August 09, 2023. The analysts firm previously had a Hold rating on the stock.Eli Lilly and Company (LLY) has been rated Overweight by analysts. According to 1 brokerage firm, LLY is a sell, and 6 firms recommend it is a Hold. There are 1 analyst who say the stock is underweight. A total of 1 analyst rate Eli Lilly and Company stock as buy, with 21 recommending it as overweight.
With a median target price of $590.00, the current consensus forecast for the stock is $300.00 – $633.00. Based on these forecasts, analysts predict Eli Lilly and Company (LLY) will achieve an average price target of $545.75.
